Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
Agree Realty(ADC) globenewswire.com·2024-05-28 18:30- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Receiving Trilaci ...